RYR1 and heart failure: Carvedilol, a beta-blocker commonly used to treat and manage heart failure and cardiac arrhythmias, suppresses store overload-induced calcium release (SOICR) in HEK-293 cells expressing MH/CCD-associated RYR1 variants in different regions of the RyR1 channel, including leaky N-terminal variants [130].